Review article: Overlap syndromes and autoimmune liver disease

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 6, 2012, Pages 517-533

  Trivedi, P J ^a   Hirschfield, G M ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN ANTIBODY; ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ASIALOGLYCOPROTEIN RECEPTOR ANTIBODY; ASPARTATE AMINOTRANSFERASE; AUTOANTIBODY; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; LIVER CYTOSOL 1 ANTIBODY; LIVER KIDNEY MICROSOMAL ANTIBODY; MITOCHONDRION ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANCREAS ENZYME; PREDNISOLONE; SMOOTH MUSCLE ANTIBODY; SOLUBLE LIVER PANCREAS ANTIGEN ANTIBODY; TACROLIMUS; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ACNE; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; AUTOIMMUNE LIVER DISEASE; B LYMPHOCYTE; BLOATING; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CELL DIFFERENTIATION; CLINICAL FEATURE; COMORBIDITY; DIABETES MELLITUS; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG ERUPTION; DRUG METABOLISM; FLATULENCE; GASTROINTESTINAL DISEASE; HAIR LOSS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERSTITIAL PULMONARY DISEASE; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER BIOPSY; LIVER DYSFUNCTION; LIVER HISTOLOGY; LIVER VEIN THROMBOSIS; LUNG DISEASE; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MEMORY CELL; NEUROTOXICITY; OSTEOPOROSIS; OVERLAP SYNDROME; PANCREATITIS; PATHOGENESIS; PORTAL VEIN THROMBOSIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY; SEX DIFFERENCE; SIDE EFFECT; SYSTEMATIC REVIEW; T LYMPHOCYTE; WEIGHT GAIN; WOUND HEALING;

CHOLANGITIS, SCLEROSING; DIAGNOSIS, DIFFERENTIAL; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS, BILIARY; PHENOTYPE; SYNDROME;

EID: 84865517962     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05223.x     Document Type: Review

References (138)

1. Zhao L, Tang Y, You Z, et al,. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One 2011; 6: e18909.
2. Longhi MS, Mitry RR, Samyn M, et al,. Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells. Hepatology 2009; 50: 130-42.
3. Longhi MS, Hussain MJ, Bogdanos DP, et al,. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology 2007; 46: 472-84. (Pubitemid 47344783)
4. Longhi MS, Meda F, Wang P, et al,. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 2008; 47: 581-91. (Pubitemid 351280726)
5. Longhi MS, Hussain MJ, Kwok WW, Mieli-Vergani G, Ma Y, Vergani D,. Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis. Hepatology 2011; 53: 536-47.
6. Longhi MS, Liberal R, Holder B, et al,. Inhibition of interleukin-17 promotes differentiation of CD25- cells into Stable T regulatory cells in patients with autoimmune hepatitis. Gastroenterology 2012; 142: 1526-35.
7. Vergani D, Mieli-Vergani G, Mondelli M, Portmann B, Eddleston AL,. Immunoglobulin on the surface of isolated hepatocytes is associated with antibody-dependent cell-mediated cytotoxicity and liver damage. Liver 1987; 7: 307-15. (Pubitemid 18013807)
8. Mayo MJ, Mosby JM, Jeyarajah R, et al,. The relationship between hepatic immunoglobulin production and CD154 expression in chronic liver diseases. Liver Int 2006; 26: 187-96.
9. Jensen DM, McFarlane IG, Portmann BS, Eddleston AL, Williams R,. Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med 1978; 299: 1-7. (Pubitemid 8387363)
10. Ma Y, Okamoto M, Thomas MG, et al,. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 35: 658-64. (Pubitemid 34183971)
11. Wen L, Peakman M,. T-cell-directed hepatocyte damage in autoimmune chronic active hepatitis. Lancet 1990; 336: 1527-30.
12. Manns MP, Vergani D,. Autoimmune hepatitis. Semin Liver Dis 2009; 29: 239-40.
13. Mieli-Vergani G, Vergani D,. Autoimmune hepatitis. Nat Rev Gastroenterol Hepatol 2011; 8: 320-9.
14. Liston A, Gray DH, Lesage S, et al,. Gene dosage-limiting role of Aire in thymic expression, clonal deletion, and organspecific autoimmunity. J Exp Med 2004; 200: 1015-26. (Pubitemid 39431126)
15. Donaldson PT,. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut 2004; 53: 599-608. (Pubitemid 38372988)
16. Oliveira LC, Porta G, Marin ML, Bittencourt PL, Kalil J, Goldberg AC,. Autoimmune hepatitis, HLA and extended haplotypes. Autoimmun Rev 2011; 10: 189-93.
17. Lucena MI, Molokhia M, Shen Y, et al,. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011; 141: 338-47.
18. Singh G, Palaniappan S, Rotimi O, Hamlin PJ,. Autoimmune hepatitis triggered by hepatitis A. Gut 2007; 56: 304.
19. Lenzi M, Bellentani S, Saccoccio G, et al,. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut 1999; 45: 435-41. (Pubitemid 29400723)
20. Gregorio GV, Choudhuri K, Ma Y, Vegnente A, Mieli-Vergani G, Vergani D,. Mimicry between the hepatitis B virus DNA polymerase and the antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis B virus infection. J Immunol 1999; 162: 1802-10. (Pubitemid 29307061)
21. Gregorio GV, Choudhuri K, Ma Y, et al,. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin Exp Immunol 2003; 133: 404-13. (Pubitemid 37046966)
22. Holdener M, Hintermann E, Bayer M, et al,. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med 2008; 205: 1409-22. (Pubitemid 351831496)
23. Vergani D, Mieli-Vergani G, Alberti A, et al,. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med 1980; 303: 66-71. (Pubitemid 10073314)
24. Czaja AJ,. Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011; 56: 958-76.
25. Hirschfield GM, Invernizzi P,. Progress in the genetics of primary biliary cirrhosis. Semin Liver Dis 2011; 31: 147-56.
26. Invernizzi P,. Human leukocyte antigen in primary biliary cirrhosis: an old story now reviving. Hepatology 2011; 54: 714-23.
27. Folseraas T, Melum E, Franke A, Karlsen TH,. Genetics in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2011; 25: 713-26.
28. Manns MP, Griffin KJ, Sullivan KF, et al,. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991; 88: 1370-8.
29. Strassburg CP, Obermayer-Straub P, Alex B, et al,. Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. Gastroenterology 1996; 111: 1576-86. (Pubitemid 26404222)
30. Wies I, Brunner S, Henninger J, et al,. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000; 355: 1510-5. (Pubitemid 30237358)
31. Kanzler S, Weidemann C, Gerken G, et al,. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 1999; 31: 635-40. (Pubitemid 29487684)
32. Bogdanos DP, Komorowski L,. Disease-specific autoantibodies in primary biliary cirrhosis. Clin Chim Acta 2011; 412: 502-12.
33. Dinani AM, Fischer SE, Mosko J, Guindi M, Hirschfield GM,. Patients with Autoimmune hepatitis who have antimitochondrial antibodies need long-term follow-up to detect late development of primary biliary cirrhosis. Clin Gastroenterol Hepatol 2012; 10: 682-4.
34. Mehendiratta V, Mitroo P, Bombonati A, et al,. Serologic markers do not predict histologic severity or response to treatment in patients with autoimmune hepatitis. Clin Gastroenterol Hepatol 2009; 7: 98-103.
35. Czaja AJ,. Cryptogenic chronic hepatitis and its changing guise in adults. Dig Dis Sci 2011; 56: 3421-38.
36. Levy C, Lindor KD,. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin Liver Dis 2006; 26: 22-30. (Pubitemid 43320724)
37. Pokorny CS, Norton ID, McCaughan GW, Selby WS,. Anti-neutrophil cytoplasmic antibody: a prognostic indicator in primary sclerosing cholangitis. J Gastroenterol Hepatol 1994; 9: 40-4. (Pubitemid 24041947)
38. Bansi DS, Bauducci M, Bergqvist A, et al,. Detection of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: a comparison of the alkaline phosphatase and immunofluorescent techniques. Eur J Gastroenterol Hepatol 1997; 9: 575-80. (Pubitemid 27267688)
39. Terjung B, Söhne J, Lechtenberg B, et al,. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 2010; 59: 808-16.
40. Hov JR, Boberg KM, Karlsen TH,. Autoantibodies in primary sclerosing cholangitis. World J Gastroenterol 2008; 14: 3781-91.
41. Vuppalanchi R, Gould RJ, Wilson LA, et al,. Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. Hepatol Int 2012; 6: 379-85.
42. Zeman MV, Hirschfield GM,. Autoantibodies and liver disease: uses and abuses. Can J Gastroenterol 2010; 24: 225-31.
43. Czaja AJ, Carpenter HA,. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006; 43: 532-8.
44. Al Chalabi T, Boccato S, Portmann BC, Mcfarlane IG, Heneghan MA,. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006; 45: 575-83. (Pubitemid 44307378)
45. Verslype C, George C, Buchel E, Nevens F, van Steenbergen W, Fevery J,. Diagnosis and treatment of autoimmune hepatitis at age 65 and older. Aliment Pharmacol Ther 2005; 21: 695-9. (Pubitemid 40468997)
46. Gregorio GV, Portmann B, Reid F, et al,. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997; 25: 541-7. (Pubitemid 27106430)
47. Stravitz RT, Lefkowitch JH, Fontana RJ, et al,. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology 2011; 53: 517-26.
48. Iwai M, Jo M, Ishii M, Mori T, Harada Y,. Comparison of clinical features and liver histology in acute and chronic autoimmune hepatitis. Hepatol Res 2008; 38: 784-9. (Pubitemid 352015629)
49. Ichai P, Duclos-Vallee JC, Guettier C, et al,. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007; 13: 996-1003. (Pubitemid 47163192)
50. Miyake Y, Iwasaki Y, Terada R, et al,. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther 2006; 23: 1347-53.
51. Yeoman AD, Westbrook RH, Zen Y, et al,. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology 2011; 53: 926-34.
52. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ,. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42: 53-62. (Pubitemid 40911311)
53. Bergquist A, Glaumann H, Lindberg B,. Broomé Primary sclerosing cholangitis can present with acute liver failure: Report of two cases. J Hepatol 2006; 44: 1005-8.
54. Boonstra K, Beuers U, Ponsioen CY,. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012; 56: 1181-8.
55. Teufel A, Weinmann A, Kahaly GJ, et al,. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol 2010; 44: 208-13.
56. Gregorio GV, Portmann B, Karani J, et al,. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001; 33: 544-53. (Pubitemid 32185215)
57. Hennes EM, Zeniya M, Czaja AJ, et al,. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-76. (Pubitemid 351975541)
58. Al-Chalabi T, Underhill JA, Portmann BC, McFarlane IG, Heneghan MA,. Effects of serum aspartate aminotransferase levels in patients with autoimmune hepatitis influence disease course and outcome. Clin Gastroenterol Hepatol 2008; 6: 1389-95.
59. Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP,. International Autoimmune Hepatitis Group. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011; 54: 374-85.
60. Trivedi PJ, Chapman RW,. PSC, AIH and overlap syndrome in IBD. Clin Res Hepatol Gastroenterol 2012 [Epub ahead of print].
61. Czaja AJ, Carpenter HA,. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001; 34: 659-65. (Pubitemid 32927988)
62. Rust C, Beuers U,. Overlap syndromes among autoimmune liver diseases. World J Gastroenterol 2008; 14: 3368-73.
63. Woodward J, Neuberger J,. Autoimmune overlap syndromes. Hepatology 2001; 33: 994-1002. (Pubitemid 32246651)
64. Joshi S, Cauch-Dudek K, Wanless IR, et al,. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002; 35: 409-13. (Pubitemid 34106382)
65. O'Brien C, Joshi S, Feld JJ, et al,. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 2008; 48: 550-6.
66. Tanaka A, Harada K, Ebinuma H, et al,. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: a rationale for corticosteroids use based on a nation-wide retrospective study in Japan. Hepatol Res 2011; 41: 877-86.
67. Chazouilleres O, Wendum D, Serfaty L, Rosmorduc O, Poupon R,. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2006; 44: 400-6. (Pubitemid 43069223)
68. Czaja AJ,. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998; 28: 360-5. (Pubitemid 28363659)
69. Gossard AA, Lindor KD,. Development of autoimmune hepatitis in primary biliary cirrhosis. Liver Int 2007; 27: 1086-90. (Pubitemid 47399442)
70. Poupon R, Chazouilleres O, Corpechot C, Chretien Y,. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006; 44: 85-90. (Pubitemid 44049141)
71. Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R,. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28: 296-301. (Pubitemid 28363652)
72. Bonder A, Retana A, Winston DM, Leung J, Kaplan MM,. Prevalence of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol 2011; 9: 609-12.
73. Muratori P, Granito A, Pappas G, et al,. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol 2009; 104: 1420-5.
74. Abdo AA, Bain VG, Kichian K, Lee SS,. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology 2002; 36: 1393-9. (Pubitemid 35403530)
75. Floreani A, Rizzotto ER, Ferrara F, et al,. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005; 100: 1516-22. (Pubitemid 41032356)
76. Abdalian R, Dhar P, Jhaverik K, et al,. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008; 47: 949-57. (Pubitemid 351449686)
77. Lewin M, Vilgrain V, Ozeme V, et al,. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology 2009; 50: 528-37.
78. Perdigoto R, Carpenter HA, Czaja AJ,. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992; 14: 325-31.
79. Gregorio GV, Portmann B, Karani J, et al,. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001; 33: 544-53. (Pubitemid 32185215)
80. Czaja AJ,. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008; 48: 1540-8.
81. Muratori P, Granito A, Pappas G, Muratori L,. Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients. Hepatology 2009; 49: 1782-3.
82. Qiu D, Wang Q, Wang H, et al,. Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients. J Hepatol 2011; 54: 340-7.
83. Yeoman AD, Westbrook RH, Al-Chalabi T, et al,. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology 2009; 50: 538-45.
84. Boberg KM, Lohse AW, Hennes EM, et al,. Assessment of 479 patients with autoimmune liver diseases according to the IAIHG scoring system for autoimmune hepatitis does not support the contention of overlap syndromes as separate diagnostic entities. Hepatology 2009; 50: 1009A.
85. Papamichalis PA, Zachou K, Koukoulis GK, et al,. The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders. J Autoimmune Dis 2007; 4: 3.
86. Gleeson D, Heneghan MA,; British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011; 60: 1611-29.
87. Manns MP, Czaja AJ, Gorham JD, et al,. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-213.
88. Montano-Loza AJ, Carpenter HA, Czaja AJ,. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 2007; 46: 1138-45. (Pubitemid 350144778)
89. Johnson PJ, McFarlane IG, Williams R,. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl.J Med 1995; 333: 958-63.
90. Hoeroldt B, McFarlane E, Dube A, et al,. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 2011; 140: 1980-9.
91. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A,. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004; 99: 1510-6. (Pubitemid 39180099)
92. Tripathi D, Neuberger J,. Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease. Semin Liver Dis 2009; 29: 286-96.
93. Corpechot C, Abenavoli L, Rabahi N, et al,. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008; 48: 871-7.
94. Kuiper EM, Hansen BE, de Vries RA, et al,. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136: 1281-7.
95. Muratori P, Granito A, Quarneti C, et al,. Autoimmune hepatitis in Italy: the Bologna experience. J Hepatol 2009; 50: 1210-8.
96. Al-Chalabi T, Portmann BC, Bernal W, McFarlane IG, Heneghan MA,. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther 2008; 28: 209-20. (Pubitemid 351861961)
97. Silveira MG, Talwalkar JA, Angulo P, Lindor KD,. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol 2007; 102: 1244-50. (Pubitemid 46802005)
98. Boberg KM, Egeland T, Schrumpf E,. Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scand J Gastroenterol 2003; 38: 991-5. (Pubitemid 37158028)
99. Olsson R, Glaumann H, Almer S, et al,. High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Intern Med 2009; 20: 190-6.
100. Beuers U, Boberg KM, Chapman RW, et al,. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J Hepatol 2009; 51: 237-67.
101. Chapman R, Fevery J, Kalloo A, et al,. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-78.
102. van Buuren HR, van Hoogstraten HJE, Terkivatan T, Schalm SW, Vleggaar FP,. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 2000; 33: 543-8.
103. Poropat G, Giljaca V, Stimac D, Gluud C,. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev 2011; 1: CD003626.
104. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB,. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000; 31: 1231-8. (Pubitemid 30351283)
105. Kaya M, Angulo P, Lindor KD,. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 2000; 33: 537-42.
106. Lüth S, Kanzler S, Frenzel C, et al,. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. J Clin Gastroenterol 2009; 43: 75-80.
107. Czaja AJ, Carpenter HA,. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006; 43: 532-8.
108. Al Chalabi T, Boccato S, Portmann BC, Mcfarlane IG, Heneghan MA,. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006; 45: 575-83. (Pubitemid 44307378)
109. Verslype C, George C, Buchel E, Nevens F, van Steenbergen W, Fevery J,. Diagnosis and treatment of autoimmune hepatitis at age 65 and older. Aliment Pharmacol Ther 2005; 21: 695-9. (Pubitemid 40468997)
110. Czaja AJ,. Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. Drugs Aging 2008; 25: 219-39. (Pubitemid 351363754)
111. Poupon R,. Treatment of primary biliary cirrhosis with ursodeoxycholic acid, budesonide and fibrates. Dig Dis 2011; 29: 85-8.
112. Zachou K, Oikonomou K, Renaudineau Y, et al,. Anti-α actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1. Aliment Pharmacol Ther 2012; 35: 116-25.
113. Danielsson A, Prytz H,. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994; 8: 585-90. (Pubitemid 24381357)
114. Czaja AJ, Lindor KD,. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000; 119: 1312-6.
115. Csepregi A, Rocken C, Treiber G, Malfertheiner P,. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol 2006; 12: 1362-6.
116. Zandieh I, Krygier D, Wong V, et al,. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol 2008; 22: 388-92. (Pubitemid 351772333)
117. Manns MP, Woynarowski M, Kreisel W, et al,. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139: 1198-206.
118. Mederacke I, Helfritz F, Puls F, et al,. Budd-Chiari syndrome after treatment with budesonide in a cirrhotic patient with autoimmune hepatitis. Ann Hepatol 2012; 11: 143-4.
119. Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T,. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 2003; 38: 196-202. (Pubitemid 36775811)
120. Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G,. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009; 51: 156-60.
121. Richardson PD, James PD, Ryder SD,. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000; 33: 371-5. (Pubitemid 30663373)
122. Hlivko JT, Shiffman ML, Stravitz RT, et al,. A Single Center Review of the Use of Mycophenolate Mofetil in the Treatment of Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2008; 6: 1036-40.
123. Hennes EM, Oo Y, Schramm C, et al,. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008; 103: 3063-70.
124. Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN,. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol 2011; 55: 636-46.
125. Baven-Pronk AM, Coenraad MJ, van Buuren HR, et al,. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther 2011; 34: 335-43.
126. Person JL, McHutchison JG, Fong TL, et al,. A case of cyclosporine-sensitive, steroid-resistant, autoimmune chronic active hepatitis. J Clin Gastroenterol 1993; 17: 317-20. (Pubitemid 23360387)
127. Sherman KE, Narkewicz M, Pinto PC,. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994; 21: 1040-7.
128. Jackson LD, Song E,. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995; 36: 459-61.
129. Alvarez F, Ciocca M, Canero-Velasco C, et al,. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999; 30: 222-7. (Pubitemid 29071183)
130. Sciveres M, Caprai S, Palla G, et al,. Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents. Aliment Pharmacol Ther 2004; 19: 209-17. (Pubitemid 38174890)
131. Cuarterolo M, Ciocca M, Velasco CC, et al,. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr 2006; 43: 635-9. (Pubitemid 44863691)
132. Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC,. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004; 38: 805-9. (Pubitemid 39274185)
133. Larsen FS, Vainer B, Eefsen M, Bjerring PN, Hansen BA,. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007; 13: 3232-6. (Pubitemid 47064587)
134. Tannous MM, Cheng J, Muniyappa K, et al,. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther 2011; 34: 405-7.
135. Kanzler S, Gerken G, Dienes HP,. Meyer zum Buschenfelde KH, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis-report of three cases. Z Gastroenterol 1997; 35: 571-8. (Pubitemid 27321630)
136. Czaja AJ, Carpenter HA, Lindor KD,. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999; 30: 1381-6.
137. Nakamura K, Yoneda M, Yokohama S, et al,. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998; 13: 490-5.
138. Hirschfield GM, Heathcote EJ,. Autoimmune hepatitis and overlap syndromes. In:, Dooley JS, Lok ASF, Burroughs AK, Heathcote EJ, eds. Sherlock's Diseases of the Liver and Biliary System, 12th edn. Oxford: Wiley-Blackwell Publishing, 2012; doi: 10.1002/9781444341294.ch23.